Targeted Therapies for Lung Cancer

Targeted Therapies for Lung Cancer

 
Edition number: 1st ed. 2019
Publisher: Springer
Date of Publication:
Number of Volumes: 1 pieces, Book
 
Normal price:

Publisher's listprice:
EUR 139.09
Estimated price in HUF:
57 395 HUF (54 662 HUF + 5% VAT)
Why estimated?
 
Your price:

52 803 (50 289 HUF + 5% VAT )
discount is: 8% (approx 4 592 HUF off)
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
 
Availability:

Uncertain availability. Please turn to our customer service.
Can't you provide more accurate information?
 
 
 
 
 
Product details:

ISBN13:9783030178345
ISBN10:303017834X
Binding:Paperback
No. of pages:238 pages
Size:235x155 mm
Weight:454 g
Language:English
Illustrations: 19 Illustrations, color; 50 Tables, color
0
Category:
Short description:

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient?s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

Long description:

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient?s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

Table of Contents:
1. EGFR
-
-Karen Reckamp, COH

 

2. ALK
-
-Ludmila B., UCSD

 

3. ROS1
-
-Jonathan Reiss, UC Davis

 

4. B
-RAF
-
-Trevor Bono, UCSF

 

5. MET?Ravi Salgia, COH

 

6. HER2
-
-Hatim Hussain, UCSD

 

7. TRK
-
-Erminia Masserelli, COH

 

8. SCLC
-
-Mariana Koczywas, COH

 

9. Immunotherapy
-
-Jonathan Goldman, UCLA

 

10. KRAS
-
-Jorge Nieva, USC

 

11. VEGF/VEGFR
-
-Ron Natale, Cedars